Asymptomatic Patient Testing After 10:1 Pooling Using the Xpert Xpress SARS-CoV-2 Assay

被引:0
作者
Procop, Gary W. [1 ]
Tuohy, Marion [1 ]
Ramsey, Christine [1 ]
Rhoads, Daniel D. [1 ]
Rubin, Brian P. [1 ]
Figler, Richard [2 ]
机构
[1] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin, Sports Med, Cleveland, OH 44106 USA
关键词
SARS-CoV-2; COVID-19; Pooling; Xpert Xpress SARS-CoV-2 assay; Coronavirus;
D O I
10.1093/AJCP/AQAA273
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: Pool testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) preserves testing resources at the risk of missing specimens through specimen dilution. Methods: To determine whether SARS-CoV-2 specimens would be missed after 10:1 pooling, we identified 10 specimens with midrange (ie, 25-34 cycles) and 10 with late (ie, >34-45 cycles) crossing threshold (Ct) values and tested these both neat and after 10:1 pooling. Final test results and Ct changes were compared. Results: Overall, 17 of 20 specimens that contained SARS-CoV-2 were detected after 10:1 pooling with the Xpert Xpress SARS-CoV-2 Assay (Cepheid), rendering an 85% positive percentage of agreement. A1110 of 10 specimens with an undiluted Ct in the mid-Ct range were detected after 10:1 pooling, in contrast to 7 of 10 with an undiluted Ct in the late-Ct range. The overall Ct difference between the neat testing and the 10:1 pool was 2.9 cycles for the N2 gene target and 3 cycles for the E gene target. The N2 gene reaction was more sensitive than the E gene reaction, detecting 16 of 20 positive specimens after 10:1 pooling compared with 9 of 20 specimens. Conclusions: An 85% positive percentage of agreement was achieved, with only specimens with low viral loads being missed following 10:1 pooling 'The average impact on both reverse transcription polymerase chain reactions within this assay was about 3 cycles.
引用
收藏
页码:522 / 526
页数:5
相关论文
共 14 条
[1]  
Abdalhamid B, 2020, AM J CLIN PATHOL, V153, P715, DOI [10.1093/AJCP/AQAA064, 10.1093/ajcp/aqaa064, 10.1101/2020.04.03.20050195]
[2]  
[Anonymous], 2020, NEUROPSYCHOBIOLOGY, DOI DOI 10.1159/000505601
[3]  
Benefield AE, 2020, MEDRXIV, DOI DOI 10.1101/2020.09.28.20202028
[4]   Challenges and Controversies to Testing for COVID-19 [J].
Binnicker, Matthew J. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (11)
[5]   Pooled nucleic acid testing strategy for monitoring HIV-1 treatment in resource limited settings [J].
Boobalan, J. ;
Dinesha, T. R. ;
Gomathi, S. ;
Elakkiya, E. ;
Pradeep, A. ;
Chitra, D. ;
Murugavel, K. G. ;
Balakrishnan, P. ;
Shantha, S. ;
Solomon, S. S. ;
Kumarasamy, N. ;
Smith, D. M. ;
Saravanan, S. .
JOURNAL OF CLINICAL VIROLOGY, 2019, 117 :56-60
[6]  
Centers for Disease Control and Prevention, 2020, OC TEST SARS COV 2 C
[7]   Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2 [J].
Chen, Jonathan Hon-Kwan ;
Yip, Cyril Chik-Yan ;
Poon, Rosana Wing-Shan ;
Chan, Kwok-Hung ;
Cheng, Vincent Chi-Chung ;
Hung, Ivan Fan-Ngai ;
Chan, Jasper Fuk-Woo ;
Yuen, Kwok-Yung ;
To, Kelvin Kai-Wang .
EMERGING MICROBES & INFECTIONS, 2020, 9 (01) :1356-1359
[8]   Occult HBV infection in HIV-infected adults and evaluation of pooled NAT for HBV [J].
Dinesha, T. R. ;
Boobalan, J. ;
Sivamalar, S. ;
Subashini, D. ;
Solomon, S. S. ;
Murugavel, K. G. ;
Balakrishnan, P. ;
Smith, D. M. ;
Saravanan, S. .
JOURNAL OF VIRAL HEPATITIS, 2018, 25 (06) :718-723
[9]   Evaluation of sample pooling for diagnosis of COVID-19 by real time-PCR: A resource-saving combat strategy [J].
Garg, Jaya ;
Singh, Vikramjeet ;
Pandey, Pranshu ;
Verma, Ashish ;
Sen, Manodeep ;
Das, Anupam ;
Agarwal, Jyotsna .
JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (03) :1526-1531
[10]   Laboratories and Pandemic Preparedness A Framework for Collaboration and Oversight [J].
Kaul, Karen L. .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (07) :841-843